EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FIP1L1- platelet-derived growth factor receptor A -positive chronic eosinophilic leukemia showing dramatic response to imatinib

Mohammad Abu-Tineh, Esra’a Aljaloudi, Aliaa Amer, Firyal Ibrahim, Wanis H. Ibrahim, Hussam Alhasson, Mohamed A. Yassin

Medicine: Case Reports and Study Protocols · 2021

DOI: 10.1097/md9.0000000000000019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicine: Case Reports and Study Protocols, 2021. Verfasst von Mohammad Abu-Tineh und 6 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Eosinophilia associated with FIP1L1- platelet-derived growth factor receptor A (PDGFRA) rearrangement is one of a subgroup of chronic eosinophilic leukemia, The 2008 World Health Organization classification of tumors of hematopoietic and lymphoid tissues established a new category for myeloid and lymphoid neoplasms with eosinophilia and abnormalities in PDGFRA, platelet-derived growth factor receptor Beta (PDGFRB) or Fibroblast growth factor receptor 1. The number of reported cases is limited worldwide, with limited data on the best modality of treatment of such disease. Patient concerns: A 48-year-old male patient with recurrent visits to the hospital presenting with multiple vague symptoms but found to have persistent marked eosinophilia. Diagnosis: The patient was diagnosed as a case of Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA Interventions: The patient was started on Tyrosine kinase inhibitor (Imatinib) 100 mg daily. Outcomes: The patient eosinophilia has improved markedly, and the patient's eosinophils levels dropped to normal levels within 3 weeks period.

Conclusion

This case indicates that in the era of Tyrosine Kinase inhibitors such as imatinib, the prognosis of Eosinophilia associated with FIP1L1-PDGFRA rearrangement has significantly improved And Prompt treatment with imatinib can lead to complete hematological response and resolution of any organ damage involved with this disease.

Zitieren

APA

Abu-Tineh, M., Aljaloudi, E., Amer, A., Ibrahim, F., Ibrahim, W. H., Alhasson, H., & Yassin, M. A. (2021). FIP1L1- platelet-derived growth factor receptor A -positive chronic eosinophilic leukemia showing dramatic response to imatinib. Medicine: Case Reports and Study Protocols. https://doi.org/10.1097/md9.0000000000000019

Vancouver

Abu-Tineh M, Aljaloudi E, Amer A, Ibrahim F, Ibrahim WH, Alhasson H, et al. FIP1L1- platelet-derived growth factor receptor A -positive chronic eosinophilic leukemia showing dramatic response to imatinib. Medicine: Case Reports and Study Protocols. 2021. doi:10.1097/md9.0000000000000019

BibTeX
@article{AbuTineh2021,
  author = {Abu-Tineh, Mohammad and Aljaloudi, Esra’a and Amer, Aliaa and Ibrahim, Firyal and Ibrahim, Wanis H. and Alhasson, Hussam and Yassin, Mohamed A.},
  title = {FIP1L1- platelet-derived growth factor receptor A -positive chronic eosinophilic leukemia showing dramatic response to imatinib},
  journal = {Medicine: Case Reports and Study Protocols},
  year = {2021},
  doi = {10.1097/md9.0000000000000019}
}
Kostenlos starten →